$XBI $133.21 -0.70%
Covid Updates
$VERA -6.6% US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure source
$VACC +1.5% Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus source
Pipeline Updates
$APRE -3.0% Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting source
$VERA -6.6% Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 source
$DRNA +4.1% Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021 source
$KDNY +9.0% CHINOOK THERAPEUTICS PRESENTS DATA FROM BION-1301 PHASE 1/2 TRIAL IN PATIENTS WITH IGA NEPHROPATHY (IGAN) AND ATRASENTAN PROGRAM AT THE AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2021 source
$HZNP -4.6% Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week source
$KPTI +0.4% Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition source
$APLS -0.2% Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting source
$ATNX -6.7% Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition source
$GRPH -3.3% Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition source
$ATNM -4.4% Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy source
$ALLO -3.6% Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology source
$DTIL -1.2% Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology source
$MOR -1.4% MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting source
$IMAB -1.8% I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 source
$YMAB -14.3% Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis source
$BLUE +1.5% bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition source
$XNCR -1.8% Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting source
$IMGN -2.0% ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH source
$APTO 0.0% Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting source
$RNA +9.0% Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™) source
$ALXO -15.5% ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting source
$VIRX -1.3% Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting source
$KROS +27.7% Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes source
$EYEN +1.8% EYENOVIA ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 VISION-2 TRIAL OF MICROLINE FOR PRESBYOPIA source
$SGMO +19.2% Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease source
$CRTX +2.5% Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th source
$LPCN +6.3% Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH source
$XOMA +0.9% XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer source
$PTGX +2.8% Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting source
$TMDX +6.7% TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial source
$CMRX +3.7% Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma source
$BCYC +0.8% Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression source
$EPZM +0.6% Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 source
$TALS -3.1% Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting source
Financial Updates
$CNCE +27.4% CONCERT PHARMACEUTICALS ANNOUNCES $65 MILLION FINANCING source
Posted by JM
Comments